

Vitor Tumas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8331046/publications.pdf>

Version: 2024-02-01

111
papers

2,939
citations

236925

25
h-index

197818

49
g-index

122
all docs

122
docs citations

122
times ranked

4184
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Endocannabinoids in Huntington's Disease: An Exploratory Cross-Sectional Study. Journal of Huntington's Disease, 2022, , 1-5.	1.9	0
2	Levodopa-induced dyskinesias in Parkinson's disease increase cerebrospinal fluid nitric oxide metabolites levels. Journal of Neural Transmission, 2022, 129, 55-63.	2.8	6
3	Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation. Molecular Neurobiology, 2022, 59, 1140-1150.	4.0	9
4	Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson's disease cohort. Parkinsonism and Related Disorders, 2022, 102, 7-15.	2.2	2
5	Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. Movement Disorders, 2021, 36, 434-441.	3.9	12
6	Is restless legs syndrome in Parkinson disease patients associated with any specific factor?. Arquivos De Neuro-Psiquiatria, 2021, 79, 38-43.	0.8	4
7	A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. Parkinsonism and Related Disorders, 2021, 83, 37-40.	2.2	3
8	Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 1711-1715.	3.9	36
9	Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. Annals of Neurology, 2021, 90, 353-365.	5.3	48
10	Genetics of Parkinson's disease in Brazil: a systematic review of monogenic forms. Arquivos De Neuro-Psiquiatria, 2021, 79, 612-623.	0.8	3
11	Tracing the Distribution of European Lactase Persistence Genotypes Along the Americas. Frontiers in Genetics, 2021, 12, 671079.	2.3	3
12	Chronic Insomnia in Patients With Parkinson Disease: Which Associated Factors Are Relevant?. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 22-27.	2.3	12
13	Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. Journal of Psychopharmacology, 2020, 34, 189-196.	4.0	69
14	SPG15 : A Rare Correlation with Atypical Juvenile Parkinsonism Responsive to Levodopa. Movement Disorders Clinical Practice, 2020, 7, 842-844.	1.5	5
15	Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias. Journal of Neural Transmission, 2020, 127, 1359-1367.	2.8	13
16	Is Ataxia an Underestimated Symptom of Huntington's Disease?. Frontiers in Neurology, 2020, 11, 571843.	2.4	11
17	CAG repeats ≤ 34 in Ataxin-1 gene are associated with amyotrophic lateral sclerosis in a Brazilian cohort. Journal of the Neurological Sciences, 2020, 414, 116842.	0.6	2
18	Profiles of cognitive impairment in the continuum from normal cognition to Alzheimer's clinical syndrome: Contributions of the short-term memory binding tests. International Journal of Geriatric Psychiatry, 2020, 35, 1331-1340.	2.7	4

#	ARTICLE	IF	CITATIONS
19	Comparison between OSEM and FBP reconstruction algorithms for the qualitative and quantitative interpretation of brain DAT-SPECT using an anthropomorphic striatal phantom: implications for the practice. <i>Research on Biomedical Engineering</i> , 2020, 36, 77-88.	2.2	2
20	Predictors of Motor Complications in Early Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 191-192.	3.9	0
21	Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 206-216.	0.8	10
22	Validation of the Brazilian Portuguese version of the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ-BR). <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 629-637.	0.8	8
23	Direct and indirect assessment of functional abilities in patients with Parkinson's disease transitioning to dementia. <i>Dementia E Neuropsychologia</i> , 2020, 14, 171-177.	0.8	4
24	Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia. <i>European Journal of Neuroscience</i> , 2019, 49, 869-882.	2.6	9
25	Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 121-133.	3.2	41
26	Using global team science to identify genetic parkinson's disease worldwide. <i>Annals of Neurology</i> , 2019, 86, 153-157.	5.3	26
27	Time Perception of an Artwork's Manipulation Is Distorted by Patients With Parkinson's Disease. <i>Frontiers in Integrative Neuroscience</i> , 2019, 13, 6.	2.1	1
28	Factors related to excessive sleepiness in patients with Parkinson's disease. <i>Neurological Research</i> , 2019, 41, 227-233.	1.3	8
29	Global cognitive performance is associated with sleep efficiency measured by polysomnography in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 248-253.	1.8	16
30	REM sleep behavior disorder in patients with Parkinson's disease: clinical and polysomnographic characteristics. <i>Sleep and Biological Rhythms</i> , 2019, 17, 113-122.	1.0	5
31	Obstructive sleep apnea and Parkinson's disease: characteristics and associated factors. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 609-616.	0.8	16
32	Anatomic and neuropsychological findings in low-educated cognitively intact elderly from a Brazilian cohort. <i>Dementia E Neuropsychologia</i> , 2019, 13, 378-385.	0.8	4
33	The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2019, 9, 596.	2.0	23
34	The frequency of the C9orf72 expansion in a Brazilian population. <i>Neurobiology of Aging</i> , 2018, 66, 179.e1-179.e4.	3.1	13
35	Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 74, 86-90.	2.7	8
36	Epidemiological and clinical aspects of a sample of Brazilian patients with primary dystonia and the impact of the new classification on their clinical evaluation. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 821-826.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Huntington's disease-like disorders in Latin America and the Caribbean. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 10-20.	2.2	18
38	Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients. <i>Neurobiology of Aging</i> , 2018, 69, 292.e15-292.e18.	3.1	10
39	Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review. <i>Journal of the Neurological Sciences</i> , 2018, 393, 63-68.	0.6	14
40	Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. <i>Analytica Chimica Acta</i> , 2018, 1044, 12-28.	5.4	43
41	Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. <i>Journal of Psychiatric Research</i> , 2017, 90, 40-45.	3.1	27
42	A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3587-3596.	3.7	33
43	Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia. <i>Journal of Voice</i> , 2017, 31, 391.e7-391.e18.	1.5	21
44	High Frequency of Sleep Disorders in Parkinson's Disease and Its Relationship with Quality of Life. <i>European Neurology</i> , 2017, 78, 330-337.	1.4	59
45	Recalling feature bindings differentiates Alzheimer's disease from frontotemporal dementia. <i>Journal of Neurology</i> , 2017, 264, 2162-2169.	3.6	22
46	Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. <i>Npj Parkinson's Disease</i> , 2017, 3, 19.	5.3	28
47	Huntington's Disease like 2 presenting with isolated Parkinsonism. <i>Journal of the Neurological Sciences</i> , 2017, 373, 105-106.	0.6	10
48	Can anxiety increase tremors in patients with Parkinson's disease? An experimental model. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 85-88.	0.6	5
49	Bipolar disorder, a precursor of Parkinson's disease?. <i>Dementia E Neuropsychologia</i> , 2016, 10, 361-364.	0.8	3
50	Cluster analysis of cognitive performance in a sample of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 315-319.	0.8	6
51	Diagnosing social anxiety in Parkinson's disease: characteristics and frequencies according to two diagnostic criteria. <i>Revista De Psiquiatria Clinica</i> , 2016, 43, 139-142.	0.6	5
52	Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 687-689.	0.8	1
53	Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2016, 10, 333-338.	0.8	18
54	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	3.9	44

#	ARTICLE	IF	CITATIONS
55	Cytoarchitecture of nitrergic neurons in the human striatum and subthalamic nucleus. Brain Research Bulletin, 2016, 124, 129-135.	3.0	6
56	Nanomedicine to Overcome Current Parkinsonâ€™s Treatment Liabilities: A Systematic Review. Neurotoxicity Research, 2016, 30, 715-729.	2.7	17
57	Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data. ENeurologicalSci, 2016, 5, 11-14.	1.3	0
58	The interlocking finger test in patients with Parkinsonâ€™s disease and healthy subjects. Journal of Clinical Neuroscience, 2016, 29, 145-148.	1.5	9
59	Cognitive dysfunction and dementia in movement disorders. Dementia E Neuropsychologia, 2016, 10, 259-260.	0.8	4
60	Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases. CNS and Neurological Disorders - Drug Targets, 2016, 15, 976-986.	1.4	2
61	Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. Clinical Neuropharmacology, 2015, 38, 221-226.	0.7	13
62	Nitric Oxide a new player in L-DOPA-induced dyskinesia. Frontiers in Bioscience - Elite, 2015, 7, 193-221.	1.8	13
63	Effects of aging on nitrergic neurons in human striatum and subthalamic nucleus. Arquivos De Neuro-Psiquiatria, 2015, 73, 779-783.	0.8	1
64	Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised. Arquivos De Neuro-Psiquiatria, 2015, 73, 929-933.	0.8	25
65	Excessive fragmentary myoclonus in patients with Parkinsonâ€™s disease: prevalence and clinico-polysomnographic profile. Sleep and Breathing, 2015, 19, 997-1002.	1.7	10
66	Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2*. Magnetic Resonance Imaging, 2015, 33, 559-565.	1.8	215
67	An analysis of the cognitive items of the movement disorders society checklist for the diagnosis of dementia in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1260-1263.	2.2	12
68	Effects of cannabidiol in the treatment of patients with Parkinsonâ€™s disease: An exploratory double-blind trial. Journal of Psychopharmacology, 2014, 28, 1088-1098.	4.0	244
69	Mutational screening of 320 Brazilian patients with autosomal dominant spinocerebellar ataxia. Journal of the Neurological Sciences, 2014, 347, 375-379.	0.6	23
70	Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 564-566.	1.5	187
71	Cheek cellâ€™ derived Î±-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiology of Aging, 2014, 35, 418-420.	3.1	30
72	Influence of external factors on the preservation of human nervous tissue for histological studies: review article. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2014, 50, .	0.3	4

#	ARTICLE	IF	CITATIONS
73	Neuroimaging of depression in Parkinson's disease: a review. <i>International Psychogeriatrics</i> , 2013, 25, 1953-1961.	1.0	26
74	Validation and internal consistency of Patient Health Questionnaire-9 for major depression in Parkinson's disease. <i>Age and Ageing</i> , 2013, 42, 645-649.	1.6	46
75	New Perspectives in Nuclear Neurology for the Evaluation of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 301-323.	2.8	1
76	Validation of the Brazilian version of the Clinical Gait and Balance Scale and comparison with the Berg Balance Scale. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 621-626.	0.8	6
77	Mattis Dementia Rating Scale (DRS): Normative data for the Brazilian middle-age and elderly populations. <i>Dementia E Neuropsychologia</i> , 2013, 7, 374-379.	0.8	24
78	Validity of the Brazilian version of the freezing of gait questionnaire. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 599-603.	0.8	27
79	Frontal assessment battery in a Brazilian sample of healthy controls: normative data. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 278-280.	0.8	55
80	Behavioral changes on amyotrophic lateral sclerosis (ALS): a case of ALS/FTD TDP-43 proteinopathy. <i>Arquivos De Neuro-Psiquiatria</i> , 2012, 70, 232-233.	0.8	2
81	Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. <i>Journal of Psychopharmacology</i> , 2011, 25, 274-280.	4.0	66
82	Increased dopamine transporter density in Parkinson's disease patients with social anxiety disorder. <i>Journal of the Neurological Sciences</i> , 2011, 310, 53-57.	0.6	45
83	Clinical and genetic analysis of 29 Brazilian patients with Huntington's disease-like phenotype. <i>Arquivos De Neuro-Psiquiatria</i> , 2011, 69, 419-423.	0.8	12
84	Salivary α -synuclein and DJ-1: potential biomarkers for Parkinson's disease. <i>Brain</i> , 2011, 134, e178-e178.	7.6	196
85	Sleep-Related Eating Disorder in Two Patients with Early-Onset Parkinson's Disease. <i>European Neurology</i> , 2011, 66, 106-109.	1.4	13
86	Validity of the PHQ-2 for the screening of major depression in Parkinson's disease: Two questions and one important answer. <i>Ageing and Mental Health</i> , 2011, 15, 838-843.	2.8	23
87	Quality of life and depressive symptoms in Parkinson's disease. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 99-101.	1.7	5
88	Antidepressivos no Tratamento de Depressão na Doença de Parkinson. <i>Revista Neurociencias</i> , 2011, 19, 570-572.	0.0	2
89	Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 42-45.	2.2	38
90	Does the Association Between Anxiety and Parkinson's Disease Really Exist? A Literature Review. <i>Current Psychiatry Reviews</i> , 2009, 5, 29-36.	0.9	11

#	ARTICLE	IF	CITATIONS
91	Reply: Choreaâ€acanthocytosis: Report of two Brazilian cases. <i>Movement Disorders</i> , 2009, 24, 1254-1254.	3.9	1
92	Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntingtonâ€™s disease. <i>Journal of Neurology</i> , 2009, 256, 1809-1815.	3.6	37
93	Huntingtonâ€™s diseaseâ€like 2 and apparent ancestry. <i>Clinical Genetics</i> , 2009, 75, 207-207.	2.0	5
94	Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. <i>Neuroscience</i> , 2009, 159, 927-935.	2.3	73
95	Cannabidiol for the treatment of psychosis in Parkinsonâ€™s disease. <i>Journal of Psychopharmacology</i> , 2009, 23, 979-983.	4.0	262
96	A kinesthetic motor imagery study in patients with writer' cramp. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 396-401.	0.8	7
97	Trismus Induced by Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 306-307.	1.4	4
98	Huntington's diseaseâ€like 2 in Brazilâ€Report of 4 patients. <i>Movement Disorders</i> , 2008, 23, 2244-2247.	3.9	28
99	Choreaâ€acanthocytosis: Report of two Brazilian cases. <i>Movement Disorders</i> , 2008, 23, 2090-2093.	3.9	16
100	Executive cognitive tests for the evaluation of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2008, 2, 206-210.	0.8	8
101	The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. <i>Arquivos De Neuro-Psiquiatria</i> , 2008, 66, 152-156.	0.8	48
102	Visuospatial cognitive tests for the evaluation of patients with Parkinson's disease. <i>Dementia E Neuropsychologia</i> , 2008, 2, 201-205.	0.8	8
103	PrevalÃancia de depressÃ£o na doenÃa de Parkinson. <i>Revista De Psiquiatria Clinica</i> , 2008, 35, 219-227.	0.6	11
104	Sydenham's chorea: Clinical observations from a Brazilian movement disorder clinic. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 276-283.	2.2	39
105	Role of Nitric Oxide on Motor Behavior. <i>Cellular and Molecular Neurobiology</i> , 2005, 25, 371-392.	3.3	110
106	Internal consistency of a Brazilian version of the unified Huntington's disease rating scale. <i>Arquivos De Neuro-Psiquiatria</i> , 2004, 62, 977-982.	0.8	10
107	Comparison of the mechanisms of latency shift in pattern reversal visual evoked potential induced by blurring and contrast reduction. <i>Electroencephalography and Clinical Neurophysiology - Evoked Potentials</i> , 1997, 104, 96-100.	2.0	9
108	Rural or urban living and Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 1996, 54, 37-41.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Effects of Touching Sculptures on the Artistic Appreciation of Collative Emotional/Perceptual Properties. <i>Paideia</i> , 0, 30, .	0.1	0
110	Episodic memory in progressive supranuclear palsy: a neuropsychological and neuroimaging study. <i>Neurological Sciences</i> , 0, , .	1.9	1
111	The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A <i>Post Hoc</i> Exploratory Analysis of Phase 2/3 Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 0, , .	2.9	4